
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
SET UP NEEDED HERE
Are you educating yourself on and counseling your patients who smoke about e-cigarettes?






